IST
SOFHOUR Finance SOFHOUR Finance
IPO desk
Sign in
Report a bugTell us what went wrong. We read every report.

What kind of problem?

We also send the page link and your browser name, to help us fix it.

Healthcare · NIFTY 500

IPCA Laboratories Limited

NSEIPCALAB BSE524494 ISININE571A01038 SeriesEQ Listed on NSE · BSE

₹1,905.00 -33.40 (-1.72%) Updated 12 Nov, 7:17 pm IST

Open chart Back to screener
Price, daily close+49.69% in a year

Today

Open
₹1,947.50
Prev close
₹1,938.40
Day high
₹1,956.00
Day low
₹1,883.50
Volume
2.09 L
Value traded
₹39.93 Cr
Upper circuit
₹2,326.00
Lower circuit
₹1,550.80
52W high
₹2,038.00
52W low
₹1,276.10
1 month
-0.01%
6 months
+26.27%
52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹48,330 Cr
P/E (TTM)34.46
P/B5.57
Book value / share₹342.07
EPS (TTM)₹55.28
ROE16.2%
Dividend yield0.31%
Dividend (12m)₹6.00 / share
Net margin (TTM)13.4%
Operating margin22.3%
Debt / equity0.07
Current ratio2.88
EV / EBITDA21.12
Sales growth (YoY qtr)+13.83%
Profit growth (YoY qtr)+32.76%
Sales CAGR 3Y+15.60%
Profit CAGR 3Y+34.28%
Shares25.37 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

2,053180
Dec 23
2,03359.6
Mar 24
2,093192
Jun 24
2,355229
Sep 24
2,245248
Dec 24
2,24767.8
Mar 25
2,309233
Jun 25
2,557283
Sep 25
2,393326
Dec 25
2,388299
Mar 26
2,788402
Jun 26
2,910375
Sep 26

Revenue · QoQ (vs last quarter)

—-1.0%+2.9%+13%-4.7%+0.1%+2.8%+11%-6.4%-0.2%+17%+4.4%

Revenue · YoY (vs a year ago)

————+9.4%+11%+10%+8.6%+6.6%+6.3%+21%+14%

Net profit · QoQ (vs last quarter)

—-67%+223%+19%+8.1%-73%+244%+21%+15%-8.3%+34%-6.7%

Net profit · YoY (vs a year ago)

————+38%+14%+21%+23%+31%+341%+72%+33%
RevenueNet profitLine = trend
7.09
Dec 23
2.35
Mar 24
7.58
Jun 24
9.05
Sep 24
9.78
Dec 24
2.67
Mar 25
9.19
Jun 25
11.14
Sep 25
12.86
Dec 25
11.79
Mar 26
15.84
Jun 26
14.79
Sep 26

EPS (₹) · YoY (vs a year ago)

————+38%+14%+21%+23%+31%+342%+72%+33%
EPS (₹)Line = trend

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

3,773692445
FY19
4,649907606
FY20
5,4201,5441,140
FY21
5,8301,309884
FY22
6,244927471
FY23
7,7051,213547
FY24
8,9401,521738
FY25
9,6461,8921,141
FY26

Revenue · YoY (vs a year ago)

—+23%+17%+7.6%+7.1%+23%+16%+7.9%

Net profit · YoY (vs a year ago)

—+36%+88%-22%-47%+16%+35%+55%
RevenueOperating profitNet profitLine = trend

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

5,8421,4581,258
Mar 23
6,3321,388209
Mar 24
6,9481,302167
Mar 25
8,064704437
Mar 26
8,678626207
Sep 26

Shareholders' equity · YoY (vs a year ago)

—+8.4%+9.7%+16%—
Shareholders' equityBorrowingsCashLine = trend

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

856-855427
FY22
806-725507
FY23
945-1,292-553
FY24
1,321-870-283
FY25
1,142-247-754
FY26

Operations · YoY (vs a year ago)

—-5.9%+17%+40%-14%
OperationsInvestingFinancingLine = trend

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

46.3%Dec 23
46.3%Mar 24
46.3%Jun 24
46.3%Sep 24
44.7%Dec 24
44.7%Mar 25
44.7%Jun 25
44.7%Sep 25
44.7%Dec 25
44.7%Mar 26
44.7%Jun 26
44.7%Sep 26
Promoter & groupPublic

Latest (30 Sep 2026)

44.7%promoter
Promoter & group
44.72%
Public (FIIs, mutual funds, retail…)
55.28%
Promoter change, last quarter
0.00 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

  • Dividend - Rs 6 Per Share
  • Dividend - Rs 2 Per Share
  • Interim Dividend - Rs 2 Per Share
  • Annual General Meeting/Dividend - Rs 2 Per Share
  • Interim Dividend - Rs 2 Per Share
  • Interim Dividend - Rs 4 Per Share
  • Annual General Meeting
  • Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share

Board meetings

  • the financial results for the period ended September 30, 2026
  • Ipca Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Fi…
  • the financial results for the period ended Jun 30, 2026
  • Ipca Laboratories Limited has informed the Exchange about Board Meeting to be held on 13-Aug-2026 to inter-alia consider and approve the Unaudited Fi…
  • the financial results for the period ended March 31, 2026 and dividend

Filings with NSE

  • Analysts/Institutional Investor Meet/Con. Call Updates
  • Copy of Newspaper Publication
  • Analysts/Institutional Investor Meet/Con. Call Updates
  • Outcome of Board Meeting
  • Analysts/Institutional Investor Meet/Con. Call Updates
  • Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Trading Window

About

About IPCA Laboratories Limited

Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients (APIs), covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name
IPCA Laboratories Limited
NSE symbol
IPCALAB
BSE scrip code
524494
ISIN
INE571A01038
Listed on
NSE, BSE
Series
EQ (normal equity)
Listed on NSE since
8 Feb 1995
Face value
₹1 per share
Market lot
1 share
Shares issued
25.37 crore
Index
NIFTY 500
Sector (NSE)
Healthcare
Industry
Pharmaceuticals: Major
Managing director / CEO
Pranay Godha
Chair
Premchand Godha
Headquarters
Mumbai
Registered address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067, Maharashtra, India
Founded
1949
Employees
23,467
Financial year
April to March
Results basis
Consolidated

Peers

Other Healthcare stocks

  1. DIVISLABDivi's Laboratories ₹11,485.00 +1.04%
  2. ALKEMAlkem Laboratories ₹5,302.00 -2.68%
  3. GRANULESGranules India ₹840.50 +5.16%
  4. SUNPHARMASun Pharmaceutical Industries ₹1,885.00 -0.91%
  5. LAURUSLABSLaurus Labs ₹2,400.00 -1.19%
  6. AUROPHARMAAurobindo Pharma ₹1,807.20 -1.11%
  7. ACUTAASAcutaas Chemicals ₹3,996.10 +2.02%
  8. APOLLOHOSPApollo Hospitals Enterprise ₹8,515.00 -1.03%

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.